JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical (Q38065100)

28 August 2017

1 reference

title

JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical (English)

1 reference

28 August 2017

0 references

Yoshiya Tanaka

1

1 reference

PubMed ID

23212593

28 August 2017

Kunihiro Yamaoka

series ordinal

2

1 reference

PubMed ID

23212593

28 August 2017

language of work or name

1 reference

5 December 2012

1 reference

28 August 2017

1 reference

28 August 2017

23

1 reference

28 August 2017

3

1 reference

28 August 2017

415-424

1 reference

Treating rheumatoid arthritis to target: recommendations of an international task force

28 August 2017

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Tyrosine kinases as targets for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

21 January 2018

The Janus kinases (Jaks)

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Jak3 negatively regulates dendritic-cell cytokine production and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Therapeutic targeting of Janus kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0799-2

10.3109/S10165-012-0799-2

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23212593